Enzymatica: Q2 2023 initial take
Research Note
2023-07-18
08:56
Redeye provides an initial take on Enzymatica’s Q2 2023 report. Sales during the quarter amounted to SEK8.8m (SEK9.6m) compared to our sales estimate of SEK7.1m. Moreover, EBIT came in at SEK-11.2m (SEK-15.9m), and the cash position at the end of the period amounted to SEK29.1m. Overall, the results were in line with our expectations. We will provide a more in-depth update shortly; however, we do not expect to make any major estimates or valuation changes.
Gustaf Meyer
This morning, Enzymatica released its Q2 2023 report with the following results:
In our view, the results were in line with our expectations. We had anticipated lower sales compared to other quarters due to the lack of flu season and our OPEX and EBIT estimates were fairly in line with the report. We will shortly provide a more in-depth update where we do not expect to make any major changes in our estimates or valuation. We will also look into Enzymatica’s current cash position as it could be a need of a capital raising during the year.
Disclosures and disclaimers